| 1 |
Which of the following best explains why independent verification of AI-based medical device performance is crucial for their acceptance?
|
E) It verifies the ease of use and effort expectancy for medical professionals. |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
What potential barrier could prevent the effective integration of AI-based medical devices into existing medical workflows?
|
A) Increased efficiency in patient care delivery |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Considering the UTAUT model, which factor is least likely to directly impact the operational efficiency of AI-based medical devices?
|
E) Regulatory compliance |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
How does AI in medical devices enhance diagnostic accuracy?
|
A) By reducing the need for patient consultations |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which aspect of AI-based medical devices could directly improve patient outcomes?
|
B) Real-time monitoring and adjustment of treatment plans |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a key consideration for the ethical use of AI in healthcare regarding patient data?
|
E) Ensuring the physical durability of devices |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
What is the primary goal of applying AI in medical imaging?
|
C) To improve the accuracy of diagnoses from images |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
How does the facilitation condition in the UTAUT model affect the adoption of AI in healthcare?
|
D) By increasing patient demand for AI-based treatments |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What role does performance expectancy play in the acceptance of AI-based diagnostics?
|
C) It assesses the expected improvement in diagnostic accuracy and efficiency. |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
In the context of adopting new medical technologies, what is the significance of effort expectancy?
|
B) It refers to the expected ease of learning and using the technology. |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What was the statistical significance (p-value) of OMT in reducing all-cause mortality, as reported?
|
B. p=0.012 |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
By what percentage did the prescription of OMT with high-intensity statin increase from 2013 to 2018?
|
E. 38.3% |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
Which group of patients was less likely to be prescribed OMT at discharge?
|
C. Patients over 75 years old |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What was the primary outcome measured in the study?
|
A. The rate of rehospitalization |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
What combination of medications defines OMT for patients with ACS according to the study?
|
A. Aspirin, P2Y12 inhibitors, statins, beta-blockers, and ACE inhibitors or ARBs |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which factor was a strong predictor for OMT prescription at discharge?
|
B. Atrial fibrillation |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What does OMT stand for?
|
B. Optimal Medical Therapy |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What trend was observed in the prescription of OMT with high-intensity statins from 2013 to 2018?
|
A. Decreased significantly |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What was the main finding regarding the association between OMT and major adverse cardiac events (MACE)?
|
C. OMT significantly reduced the risk of MACE |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
Which factor was NOT identified as a strong predictor for OMT prescription at discharge?
|
E. Being diagnosed with NSTEMI or STEMI |
|
|
|
5 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|